Introduction: Aspirin is associated with increased bleeding during and after cardiac surgery, but
it may also reduce thrombotic complications. We do not know whether there is a net
benefit or risk from stopping aspirin. Antifibrinolytics such as tranexamic acid can
reduce bleeding after cardiac surgery, but we do not know whether antifibrinolytics
increase the risk of thrombotic complications such as MI or stroke. There are no large
randomised trials to guide our practice [
[1]
].To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Heart, Lung and CirculationAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Aprotinin and lysine analogs in high-risk cardiac surgery.N Engl J Med. 2008;
- Aspirin and tranexamic acid for coronary artery surgery (ATACAS) trial: rationale and design.Am Heart J. 2009;
Article info
Identification
Copyright
© 2011 Published by Elsevier Inc.
